United BioPharma (UBP), a spinoff company of UBI Asia, was founded by Dr. Chang Yi Wang. Dr. Wang serves as the executive Chairwoman of the Board of Directors and Chief Scientific Officer of UBP. At the invitation of the Taiwanese government in 1998, Dr. Wang set out to establish UBI-Asia, a joint venture between United Biomedical, Inc. (UBI) based in the US and the Taiwan government. She launched a state-of-the-art protein and antibody drug development platform within UBI Asia employing monoclonal antibody B4 as a touch stone and built a competent team with integrated platform technologies to enable development of antibody products from DNA to BLA filings. Other antibody and long acting protein products followed, leading to the spinoff of United Biopharma with a group of rigorously selected antibody products.
Dr. Wang’s invention, UB421, is the first antibody product in UBP’s pipeline. UB421 is an anti CD4 antibody having a unique HIV competitive binding inhibition property. UB421 is currently in multiple Proof of Concept (POC) phase II trials in combination with ART for functional cure, as well as a multinational monotherapy phase III trial for ART substitution. With CD4 being an important immune modulatory molecule, this class of antibodies with characteristic features resembling UB421 have many important first-in-human clinical applications.
In addition to antibody and long acting protein products as biologics for disease treatment, Dr. Wang is a pioneer in using designer synthetic peptides in multiple biomedical applications. Her early inventions in synthetic peptide based HIV and HCV blood screening tests have sold hundreds of millions in the global market; since 2007, her first high precision epitope based vaccine against Foot and Mouth Disease in the animal health field has sold over 4 billion doses in China, the largest global swine market; her second high precision peptide based LHRH targeted immunocastration vaccine has also been launched in the global swine market. These initial inventions have provided UBI with commercialization expertise to become an industry leader in many high precision peptide vaccine applications in disease intervention as immunotherapeutics.
Dr. Wang has received several prestigious awards, including the 2007 Inventor of the Year award from the New York Intellectual Property Law Association (NYIPLA) for her high precision UBITh immunogen designs, and the 2018 Pioneer in Technology Award from the Brain Mapping Foundation for her contribution in the development of vaccines for the treatment of Neurodegenerative Diseases.
Prior to founding UBI in 1985 and its subsequent group of companies to facilitate commercialization of her platform derived inventions, Dr. Wang was a Principal Investigator and director of the Laboratory of Molecular Immunology, endowed by the Arthur J. and Leslie Levine fund, at the Memorial Sloan-Kettering Cancer Center, a faculty member at the Sloan Kettering Institute and an adjunct associate professor at the Cornell University Medical School.
During her research career in the US, she received over US$20 million in grants and contracts from National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) of National Institutes of Health (NIH). Dr. Wang has over 120 scientific publications in peer-reviewed high impact journals such as New England Journal of Medicine, Lancet, Science, Journal of Experimental Medicine, and Journal of Infectious Diseases etc. and over 100 issued patents and additional pending patent filings. Dr. Wang received her B.S. in chemistry with honors from National Taiwan University and her Ph.D. in immunology and biochemistry from the Rockefeller University, New York, USA.
Dr. Lynn, our Chief Executive Officer joined United BioPharma (UBP) in 2013. She has been with UBI Group since 1999 and is currently one of the Executive Committee and a member of its Board Directors. Dr. Lynn led development of humanized antibody, high-producing CHO Cell Line and process development for the antibody pipelines and played key part in leading UBP’s pipeline UB-421 into early stage clinical trial.
During Dr. Lynn’s tenure at UBI Asia, the company was awarded 11 government grants leading three pipelines into clinical trial stage. Dr. Lin earned her Ph.D. in Life Sciences from the Institute of Zoology at National Taiwan University and received BSc degree in Plant Pathology from National Taiwan Univesrity.
Dr. Liao brings a track record of over 30 years of experience in biopharmaceutical industry to UBP, Dr. Liao has been with the Company since 2014. Prior to United BioPharma, she was leader for Regulatory Affairs team and function at United Biomedical between 2008 to 2013.
Her enriched experience in Research and Development in the United States brings great value to our Organization. Dr. Liao international experience include VP R&D and Quality Control, VP Regulatory Affairs and Quality at Hemispherx Biopharma; VP R&D at Interferon Sciences, and Head Cellular Immunology Group at the same company. Dr. Liao has 45 full length articles published in peer reviewed journals and presented more than 70 abstracts in scientific conferences. Dr. Liao earned her PhD, Physical Biochemistry and MPh Physical Biochemistry from Yale University. Her B.S. Chemistry was obtained from National Tsing Hua University in Taiwan.
Dr. Liu is Vice President Research and Development at United BioPharma (UBP), having joined at UBP since 2013, Dr. Liu's key responsibilities include leading projects in the major areas of genetic engineering, molecular biology, protein biochemistry, formulation study and analytical method development.
He joined the UBI Group from 2005 as a research scientist and developed analytical test methods for the release and characterization of protein drug products. Dr. Liu and his team led the CMC preparation of protein and antibody products for IND submissions. Dr. Liu's track record include succesful transfer of five biological compounds from discovery translation to clinical stage. Dr. Liu received his Ph.D. degree in Department of Life Sciences, National Tsing Hua University,
Victor Sun joined UBP in 2014 as vice president of public affairs and spokesperson. Prior to that, he was the manager and assistant to the chair at Hua Yu Lien Development Co., Ltd., and deputy executive director for the Taipei Chamber of Commerce. Victor also served as the chief secretary for not only the Overseas Community Affairs Council, Taiwan (R.O.C. ) but also the National Palace Museum. Therefore, he has extensive experience of in dealing with government agencies , public policy and management, and public negotiation . Moreover, Victor is familiar with strategic planning and commercialization. He received his BS degree from the Department of Law at National Taiwan University.
Dr. Kuo Vice President Clinical Pharmacology, brings 30 years of track record in drug development that spans from monoclonal antibody, synthetic peptide vaccine, protein and small molecule compounds. Dr. Kuo's strong research and background experience include quantitative protein and cellular analysis, immuno pharmacology, pharmacokinetics and safety/toxicology studies.
Dr. Kuo's milestones in innovative drug research and development include 10+ monoclonal antibodies used in respiratory, immunology, infectious diseases and oncology therapeutic areas. Dr. Kuo was Senior Scientist in the United States for Marion Merrell Dow (now Sanofi), Parke Davis (now Pfizer), IDEC Pharmaceutical (now Biogen Idec). and as Senior Director in Taiwan for AbGenomics and Fountain Biopharma.
Dr. Kuo joined United Biomedical, Asia (UBIA) in 2009-2010 and subsequently joined UBP in 2014. Dr. Kuo graduated from Pharmacy School of Taipei Medical University and received his Ph. D. degree in Biopharmaceutics from the College of Pharmacy, University of Cincinnati, Ohio. He remained building his strong academic experience doing postdoctoral research in cardiovascular pharmacology at Duke University and Jefferson Medical Center. Dr. Kuo published 40 peer-reviewed scientific papers.